



an Open Access Journal by MDPI

## State-of-the-Art Gene-Target and Cell Therapy in Poland

Guest Editors:

**Dr. Anita Lyssek-Borón**

Department of Ophthalmology,  
Faculty of Medicine in Zabrze,  
Academy of Silesia in Katowice,  
Katowice, Poland

**Dr. Benjamin Grabarek**

Collegium Medicum, WSB  
University, 41-300 Dabrowa  
Gornicza, Poland

Deadline for manuscript  
submissions:

**closed (31 January 2024)**

### Message from the Guest Editors

Dear Colleagues,

This Special Issue aims to publish contributions on all aspects of the study of molecular and epigenetic biology as well as gene and cell therapy in Poland. Research articles and reviews are sought which provide insight into any aspects of gene and cell therapies in Poland. Topics include but are not limited to:

- Personalized diagnostic and therapy;
- Target vectors for gene therapies;
- Molecular processes of cell division, senescence, and cell death;
- Stem-cell-based therapies;
- Cell-vehicle-targeting strategies;
- Gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics;
- Antisense oligonucleotide technology;
- Molecular mechanisms and models of disease;
- Suicide gene therapy;
- Clinical genome editing;
- Pre-clinical animal/in vitro studies to assess safety of gene and cell therapy products;
- Epigenetic aims of therapy;
- Signaling networks and system biology;
- Molecular anti-cytokine therapies in diseases with cell hyperproliferation;
- Gene and immune therapies in children and adults with a wide range of disorders;
- Gene and cellular therapies.



[mdpi.com/si/139657](https://mdpi.com/si/139657)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

## Contact Us

---

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI